From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Po
From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
What it found
No result yet.
What was tested
Treatment tested
- Biological sample collection
What it measured
Main measures
Bulk RNA-sequencing
Blood sample collection within 6 months after first inflammatory event for MS patients and at inclusion for healthy volunteers.
Thinking and memoryImmune response
Other measures (4)
Single RNA sequencing
Blood sample collection within 6 months after first inflammatory event.
Immune responseAssociation of genetic sequence variation from whole genome sequencing with gene expression profile via Bulk RNA-seq
Blood sample collection within 6 months after first inflammatory event.
Immune responseAssociation of transcriptomic variation with DNA methylation
Blood sample collection within 6 months after first inflammatory event.
Immune responseOMIC integration
Blood sample collection within 6 months after first inflammatory event.
Who could take part
Early (CIS/RIS) · 18 and over
Show the full criteria
Inclusion criteria
Common criteria for retrospective MS patients: * Patients aged 18 years or older * Clinical isolated syndrome (CIS) with or without dissemination in space * Patients affiliated to an appropriate health insurance Criteria for Aggressive MS group • Start of a 2nd line therapy within the two years following the CIS Criteria for Non aggressive MS group * No conversion according to McDonald criteria from clinical isolated syndrome to multiple sclerosis within 2 years or * Conversion based to McDonald criteria treated or not with first line disease modifying therapy within 2 years. * Have a minimum of least 2 years of follow-up. Healthy volunteers * Aged 18 years or older * No history of clinically isolated syndrome or MS Pairing criteria : * Age +/- 5 years * Sex Prospective MS Patients * Patients aged 18 years or older * Clinical isolated syndrome (CIS) with or without dissemination in space * Patients affiliated to an appropriate health insurance
Exclusion criteria
* Ongoing participation to a another study * Refusal to genetic analyses * Immunosuppressive drug at the time of blood collection * Plasma exchange or corticosteroid treatment within the four weeks prior to blood sample * Adults under a legal protection regime (guardianship, trusteeship, judicial safeguard) * Pregnancy
As registered. Criteria can change, so ask the trial team or your neurologist.
Contact details on the registryAbout this trial
In the sponsor's words
MS is a heterogeneous disease either in its response to treatment or clinical manifestation. Indeed, the natural history of MS is varying from a benign condition to a devastating and rapidly incapacitating disease. Clinical heterogeneity could also be cellular and / or molecular. The aim is to identify from OMIC analyses, at the early stage of the disease, differentially expressed molecules and / or cell subpopulations derived from CD8 + T lymphocytes and / or CD4 + T lymphocytes and / or B lymphocytes and monocytes from patients with aggressive versus non-aggressive, compared to a cohort of healthy controls
Loading reviews and guidelines…
History
Started
Jan 2022
Main results due
Jul 2029
Finished
Jul 2029